Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients
with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.